Validation of the role of apolipoproteins in coronary artery disease patients with impaired kidney function for prognosis: a prospective cohort study in China

Table 2 The relationship between various Apos and MACE risks via Cox regression

	Model1	P	Model2	P
continue
ApoB	1.642(1.074–2.510)	0.022	1.668(1.044–2.666)	0.033
ApoA1	0.435(0.285–0.663)	0.001	0.505(0.326–0.782)	0.002
ApoB/ApoA1	2.614(1.698–4.025)	0.001	2.231(1.409–3.533)	0.001
category
ApoB	1.222(1.072–1.434)	0.032	1.240(1.004–1.562)	0.037
ApoA1	0.716(0.574–0.894)	0.003	0.751(0.596–0.947)	0.016
ApoB/ApoA1	1.385(1.110–1.728)	0.004	1.341(1.064–1.691)	0.013

Model2 adjusted for sex, age, BMI, ACS, DM, HBP, family history CAD, smoking, Lesion length, MLD, stent, stent length, eGFR, TG, ARB/ACEI, CCB, aspirin, clopidogrel, statin
TG Triglycerides, BMI Body mass index, eGFR estimated glomerular filtration rate, ACS Acute coronary syndrome, DM Diabetes mellitus, MLD Minimal lumen diameter, CAD Coronary artery disease, HBP Hypertension, CCB Calcium channel blockers, ARB/ACEI Angiotensin II receptor blockers/angiotensin-converting enzyme inhibitors

ISSN: 1475-2891